GLP-1 patients face inconsistent access and regulatory uncertainty with telehealth providers

Patients seeking GLP-1 medications through telehealth face a fragmented market with varying quality standards, unclear regulatory compliance, and unpredictable access as the industry transitions from unregulated boom to stricter oversight. Current telehealth platforms lack transparency about physician credentials, medication sourcing, and legal status, leaving patients uncertain whether their provider will remain operational or compliant. This creates anxiety for people dependent on these medications for weight loss and diabetes management who can't reliably access treatment.